Publications by authors named "Johannes M Mommers"
Article Synopsis
- The study investigates the impact of psoriasis on patients' work and daily life activities as they start using biological treatments.
- Data from 194 patients showed that after beginning treatment, disease activity significantly decreased, yet work participation remained lower than the general population.
- Although employed patients exhibited improved productivity, nearly half still faced challenges in daily activities, with no significant changes observed over time.
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Acta Derm Venereol
May 2022
Article Synopsis
- A study was conducted to compare the effectiveness of different biologic therapies for psoriasis, including IL17-inhibitors and TNF-α-inhibitors, using real-world data.
- Researchers analyzed data from 1,080 treatment episodes involving 700 psoriasis patients to assess outcomes like the mean Psoriasis Area and Severity Index (PASI) and how many patients achieved PASI90 or PASI75.
- Results showed that patients on adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab had better outcomes than those on etanercept, with ixekizumab and guselkumab leading to even higher rates of achieving PASI90 compared to the other biologics
Article Synopsis
- Biologics for psoriasis can be safely reduced in dosage for patients with low disease activity to avoid overtreatment and reduce costs, though concerns about increased anti-drug antibody (ADA) formation exist.
- * The study involved 118 patients who were randomly assigned to either dose reduction (DR) or usual care (UC) over one year, examining serum drug concentrations and ADA levels.
- *Results showed no significant difference in ADA levels for adalimumab between DR and UC, and no relevant ADA development for ustekinumab; this suggests that dose tapering may not increase immunogenicity in low disease activity psoriasis patients.
A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The aim of the current study was to perform a cost-utility analysis with a 12-month time horizon alongside this trial, using prospectively measured healthcare costs and quality-adjusted life years, based on Short-Form Six-Dimension utilities. Bootstrap analys-es were used to calculate the decremental cost-utility ratio and the incremental net monetary benefit.
View Article and Find Full Text PDFImportance: Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible.
Objective: To investigate whether dose reduction (DR) of biologics in patients with stable psoriasis is noninferior to usual care (UC).